公开(公告)号：US11684640B2

公开(公告)日：2023-06-27

申请号：US16472778

申请日：2017-12-22

申请人： INSTITUT GUSTAVE ROUSSY ,  INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE-INSERM ,  UNIVERSITE PARIS-SACLAY ,  Institut national de recherche pour l'agriculture, l'alimentation et l'environnement (INRAE)

发明人： Laurence Zitvogel ,  Bertrand Routy ,  Emmanuelle Le Chatelier

IPC分类号： A61K35/744 ,  A61K39/395 ,  C12Q1/6886 ,  C12Q1/689 ,  A61K39/00

CPC分类号： A61K35/744 ,  A61K39/39558 ,  C12Q1/689 ,  C12Q1/6886 ,  A61K2039/55594 ,  A61K2039/585 ,  C12Q2600/106 ,  C12Q2600/118

摘要： The invention relates to gut microbiota profiles associated with response or resistance to treatments with ICB, in particular with anti-PD1 or anti PD-L1 or anti-PD-L2 antibodies. In particular, the invention pertains to a theranostic method for identifying good responders, to whom an anti-PD1 or anti PD-L1 or anti-PD-L2 can be administered, while a pre-treatment based on FMT and/or immunogenic probiotics is recommended to bad responders exhibiting a dysbiosis. In particular, the present invention pertains to Akkermansia muciniphila as the main commensal species distinguishing responders from progressors and its use alone or with E. hirae for the treatment of antibiotics or gut repertoire insufficiency-associated dysbiosis.

公开(公告)号：US20230183306A1

公开(公告)日：2023-06-15

申请号：US17876987

申请日：2022-07-29

申请人： Cytune Pharma ,  Institut Gustave Roussy (IGR)

发明人： David Bechard ,  Nathalie Chaput ,  Melanie Desbois

IPC分类号： C07K14/54 ,  A61K38/20 ,  G01N33/50 ,  A61K47/64 ,  C07K14/715

CPC分类号： C07K14/5443 ,  A61K38/20 ,  G01N33/5047 ,  G01N33/5011 ,  A61K47/642 ,  C07K14/7155 ,  G01N2800/52 ,  C07K2319/00

摘要： The present invention relates to a pharmaceutical composition for treating a cancer or an infection in a subject by administrating an amount of an IL-15 derivative conjugate so as to induce a proliferation of natural killer cells (NK cells) which is the same or higher than the one obtained with high dose of interleukin-2 (HDIL-2); eventually associated with a pharmaceutically acceptable carrier.

公开(公告)号：US20230000801A1

公开(公告)日：2023-01-05

申请号：US17779943

申请日：2020-11-24

申请人： CLEVEXEL PHARMA ,  INSTITUT GUSTAVE ROUSSY ,  UNIVERSITE PARIS-SACLAY

发明人： Denis BRICOUT ,  Xiuping WANG-ZHANG ,  Eric DEUTSCH ,  Céline CLEMENSON

IPC分类号： A61K31/145 ,  A61K9/19 ,  A61K47/34 ,  A61K47/26 ,  A61K9/06

摘要： A freeze-dried powder for preparing a thermogel including: from 1% to 35% of 2-[(3-aminopropyl)amino]ethanethiol or one of its pharmaceutically acceptable salt; from 40% to 85% of one or more poloxamer; and from 0.1% to 20% of one or more carbohydrate compound.

公开(公告)号：US11517575B2

公开(公告)日：2022-12-06

申请号：US16963338

申请日：2019-01-23

申请人： Institut Gustave-Roussy

发明人： Jean Luc Perfettini ,  Eric Deutsch ,  Catherine Brenner ,  Jean-Christophe Cintrat ,  Frederic Taran

IPC分类号： A61K31/5377 ,  A61K31/15 ,  A61K31/4166 ,  A61K31/513 ,  A61N5/10 ,  G01N33/50 ,  A61P35/00 ,  A61K9/00

摘要： The present invention is drawn to the use of Minaprine dihydrochloride and analogs thereof, for reducing tumor growth when administered to a patient suffering from cancer.

公开(公告)号：US11466327B2

公开(公告)日：2022-10-11

申请号：US16313659

申请日：2017-07-03

申请人： INSTITUT GUSTAVE ROUSSY ,  ISTITUTO EUROPEO DI ONCOLOGIA (IEO)

发明人： Michiels Stefan ,  Mohamed Amine Bayar ,  Fabrice Andre ,  Carmen Criscitiello ,  Giuseppe Curigliano

IPC分类号： C12Q1/6886

摘要： The present invention relates to the use of the value of the expression of at least one gene selected from the group comprising: GBP 1 gene, HLF gene, CXCL13 gene and SULT1E1 gene, for the estimation of prognosis of distant relapse-free survival or overall survival of a patient with triple negative breast cancer (TNBC) having received a neoadjuvant chemotherapy (NACT).

公开(公告)号：US20220257709A1

公开(公告)日：2022-08-18

申请号：US17626360

申请日：2020-07-17

申请人： Institut Gustave-Roussy

发明人： Jean-Luc PERFETTINI ,  Awatef ALLOUCH ,  Eric DEUTSCH

IPC分类号： A61K38/17 ,  C12N5/0786 ,  C12N15/86 ,  C12N15/90 ,  A61K35/15 ,  A61P35/02 ,  A61K45/06

摘要： Identification of effective targets alleviating the programmed cell removal (PrCR) of tumor cells by macrophages is of very high interest. The present inventors have identified that the cyclin-dependent kinase inhibitor p21 protein is a strong regulator of the macrophage-mediated PrCR. Also, they showed that the adoptive transfer of p21 overexpressing monocytes induces macrophage PrCR and transition from an anti-inflammatory to a pro-inflammatory phenotype in vivo, delays cancer progression and increases significantly the overall survival of mice engrafted with cancer cells. The present invention therefore concerns therapeutic compositions comprising monocytes that over-express the cyclin-dependent kinase inhibitor p21 protein, and their use for treating mammals suffering from cancer, especially leukemia.

公开(公告)号：US11293066B2

公开(公告)日：2022-04-05

申请号：US16631848

申请日：2018-07-17

申请人： INSTITUT GUSTAVE ROUSSY

发明人： Salem Chouaib ,  Stéphanie Buart

IPC分类号： C12Q1/68 ,  C12Q1/6886

摘要： The present invention relates to a method for assessing the response to PD-1/PDL-1 targeting drugs based on the differential expression levels of BINP3 and GBE1.

公开(公告)号：US20220056532A1

公开(公告)日：2022-02-24

申请号：US17279565

申请日：2019-09-27

申请人： INSTITUT GUSTAVE ROUSSY

发明人： Laurence ZITVOGEL ,  Valerio IEBBA

IPC分类号： C12Q1/6886 ,  C12Q1/689 ,  G06F17/18

摘要： The present invention relates to a method for in vitro determining if an individual having a renal cell cancer (RCC) is likely to respond to a treatment with an anti-PD1/PD-L1/PD-L2 Ab-based therapy, based on the analysis of the microbiota present in a stool sample from said individual. Twelve models useful to perform the above method are disclosed, as well as tools designed to easily perform this method.

公开(公告)号：US20220023342A1

公开(公告)日：2022-01-27

申请号：US17297052

申请日：2019-12-02

申请人： INSTITUT GUSTAVE ROUSSY

发明人： FATHIA MAMI-CHOUAIB ,  MARINE LECLERC ,  GEORGES BISMUTH

IPC分类号： A61K35/17 ,  C07K16/28

摘要： The present invention relates to the combined use of a neuropilin-1 (Nrp-1) neutralizing agent and of a programmed cell death-1 (PD-1) neutralizing agent for killing cancer cells, typically for treating cancer, as well as to corresponding pharmaceutical compositions and kits, and to corresponding diagnostic and therapeutic methods. The invention further relates to in vitro, ex vivo and in vivo methods for detecting CD8+ TILs capable of recognizing cancer cells, for predicting the response of a subject to anti-PD-1 treatment of cancer, and for identifying a subject who responds therapeutically to a treatment of cancer with an antibody combination therapy comprising anti-Nrp-1 and anti-PD-1 antibodies.

公开(公告)号：US11110105B2

公开(公告)日：2021-09-07

申请号：US16604599

申请日：2018-04-11

申请人： INSTITUT GUSTAVE ROUSSY

发明人： Sébastien Apcher ,  Alison Pierson ,  Mathilde Boulpicante ,  Zafiarisoa Dolor Renko ,  Mouad Alami ,  Romain Darrigrand

IPC分类号： C07D311/30 ,  A61K31/352 ,  A61K31/665 ,  A61P35/00 ,  A61K45/06

摘要： The present invention relates to the fields of medicine and cancer treatment. The invention more specifically relates to new compounds which are typically for use as a medicament. In particular, the invention relates to the use of these new compounds for increasing the presentation, typically the production and presentation, of Pioneer Translation Products (PTPs)-derived antigens by cancer cells in a subject, and inducing or stimulating an immune response in the subject. The present disclosure also relates to uses of such compounds, in particular to prepare a pharmaceutical composition and/or to allow or improve the efficiency of a cancer therapy in a subject in need thereof. The invention also discloses methods for preventing or treating cancer, cancer metastasis and/or cancer recurrence in a subject. The present invention in addition provides kits suitable for preparing a composition according to the present invention and/or for implementing the herein described methods.